Neuren Pharmaceuticals (ASX:NEU) plans to launch a share buyback program of up to 3 million shares worth AU$50 million for up to 12 months, according to a Thursday filing with the Australian bourse.
The shares to be acquired represent 2.4% of the company's total shares in issue.
The capital deployment comes as the company is poised to receive one-third of the proceeds from the sale of Neuren licensee Acadia Pharmaceuticals' Rare Pediatric Disease Priority Review Voucher for $150 million, the filing said.
The pharmaceutical company's shares were up more than 5% in recent Thursday trade.
Price (AUD): $17.44, Change: $+0.90, Percent Change: +5.44%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。